Stroke:动脉瘤性蛛网膜下腔出血患者慢性肝病与死亡率之间的关系

2021-07-20 MedSci原创 MedSci原创

在aSAH患者中,与非CLD相比,CLD与死亡率增加相关。在伴有CLD的aSAH患者中,较高的终末期肝病模型评分与死亡率增加相关。

慢性肝病 (CLD) 是急性危重病患者发病率和死亡率增加的重要危险因素。对于动脉瘤性蛛网膜下腔出血 (aSAH) 患者而言,CLD是否与这类患者死亡率之间存在相关性尚未明确。

近日,血管疾病领域权威杂志Stroke上发表了一篇研究文章,在这项回顾性队列研究中,研究人员分析了在2009年至2019年期间连续就诊且入住华西医院的aSAH患者。该研究的主要结局是aSAH患者的院内全因死亡率。

该研究共纳入了6228例aSAH患者,其中489例患者(7.9%)同时伴有CLD。在倾向性匹配分析中,与非CLD患者相比,伴有CLD与aSAH患者全因死亡率增加之间存在相关性(比值比为2.04[95%CI为1.43-2.92])。

在伴有CLD的aSAH患者中,较高的终末期肝病模型评分仍然与患者死亡率增加相关。

由此可见,在aSAH患者中,与非CLD相比,CLD与死亡率增加相关。在伴有CLD的aSAH患者中,较高的终末期肝病模型评分与死亡率增加相关。

原始出处:

Yu Zhang.et al.Association of Chronic Liver Disease and Mortality in Patients With Aneurysmal Subarachnoid Hemorrhage.stroke.2021.https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.034136

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1654515, encodeId=715b16545153d, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jan 27 00:42:58 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001872, encodeId=64a210018e209, content=值得临床治疗采纳, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Fri Jul 23 00:36:17 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337814, encodeId=6d94133e814f2, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jul 22 11:42:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001279, encodeId=9a4710012e978, content=新颖,有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29cb3032988, createdName=Zhouypwy, createdTime=Tue Jul 20 23:18:48 CST 2021, time=2021-07-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1654515, encodeId=715b16545153d, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jan 27 00:42:58 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001872, encodeId=64a210018e209, content=值得临床治疗采纳, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Fri Jul 23 00:36:17 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337814, encodeId=6d94133e814f2, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jul 22 11:42:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001279, encodeId=9a4710012e978, content=新颖,有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29cb3032988, createdName=Zhouypwy, createdTime=Tue Jul 20 23:18:48 CST 2021, time=2021-07-20, status=1, ipAttribution=)]
    2021-07-23 452946589

    值得临床治疗采纳

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1654515, encodeId=715b16545153d, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jan 27 00:42:58 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001872, encodeId=64a210018e209, content=值得临床治疗采纳, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Fri Jul 23 00:36:17 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337814, encodeId=6d94133e814f2, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jul 22 11:42:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001279, encodeId=9a4710012e978, content=新颖,有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29cb3032988, createdName=Zhouypwy, createdTime=Tue Jul 20 23:18:48 CST 2021, time=2021-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1654515, encodeId=715b16545153d, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jan 27 00:42:58 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001872, encodeId=64a210018e209, content=值得临床治疗采纳, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Fri Jul 23 00:36:17 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337814, encodeId=6d94133e814f2, content=<a href='/topic/show?id=376c332e497' target=_blank style='color:#2F92EE;'>#动脉瘤性蛛网膜下腔出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33274, encryptionId=376c332e497, topicName=动脉瘤性蛛网膜下腔出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jul 22 11:42:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001279, encodeId=9a4710012e978, content=新颖,有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29cb3032988, createdName=Zhouypwy, createdTime=Tue Jul 20 23:18:48 CST 2021, time=2021-07-20, status=1, ipAttribution=)]
    2021-07-20 Zhouypwy

    新颖,有临床指导意义

    0

相关资讯

Lancet Psychiatry:精神障碍、情绪障碍患者应优先接种COVID-19疫苗

应考虑对所有该研究中确定的高危患者优先接种疫苗。此外,需要对出现COVID-19的精神障碍患者进行密切监测和适当的医院转诊,以抵消可能减少的治疗机会。

Br J Cancer:质子泵抑制剂PPI的使用影响结直肠癌患者的生存率

质子泵抑制剂(PPI)是全球最常用的处方药之一,在所有成年人中的使用率高达11-30%。

Chest:抗纤维化治疗对特发性肺纤维化患者死亡率和急性加重的影响

抗纤维化治疗似乎降低了IPF患者的全因死亡率和AE风险。

Ann Rheum Dis:COVID-19 大流行对炎性关节病患者死亡率的影响

自2020年初COVID-19 大流行以来,很多风湿病患者不幸感染了新冠病毒。这项研究则评估了炎性关节病患者 (IJDs) 抗风湿治疗中COVID-19重症感染全因死亡的绝对和相对风险。

Crit Care:入住ICU时的血浆谷氨酰胺水平是危重病患者死亡的独立危险因素

ICU入院时高谷氨酰胺血症是一个独立的死亡率预测因子,但并非总与急性肝病相关。

JCEM:肾上腺腺瘤患者的心脏代谢结局和死亡率

在基于人群的队列中,肾上腺腺瘤与不良心脏代谢结局的患病率和发生率增加相关。